Income Statement

IMMUNOVANT, INC.

IMVT
Annual
Performance Overview Click any row in the table to add it to this chart
in millions USD
Metric Mar 31, 2025 2024 FY Mar 31, 2024 2023 FY Mar 31, 2023 2022 FY Mar 31, 2022 2021 FY Mar 31, 2021 2020 FY Mar 31, 2020 2019 FY
Revenue
- - - - - -
Cost of Revenue
- - - - - -
Gross Profit
- - - - - -
Operating Expenses
438.15 282.71 218.28 156.03 108.12 66.08
Research & Development
360.92 212.93 160.26 101.81 68.60 47.93
Selling, General & Administrative
77.24 57.28 48.02 54.23 39.51 18.15
Other Operating Expenses
- - - - - -
Operating Income
-438.15 -282.71 -218.28 -156.03 -108.12 -66.08
Non-Operating Income
-25.20 -23.94 -7.33 0.78 -0.33 0.21
Interest Income
- - - - - -
Interest Expense
- - - - 0.00 0.63
Other Non-Op Income / Expense
0.47 -1.01 -0.25 -0.78 0.33 0.41
Income Before Tax
0.00 0.00 0.00 0.00 0.00 0.02
Income Tax Expense
0.89 0.57 0.01 -0.08 -0.36 0.10
Non-Controlling Interest
- - - - - -
Net Income
-413.84 -259.34 -210.96 -156.73 -107.43 -66.39
Supplemental Per share data, derived & other items — not part of the income statement
in millions USD unless noted
Metric Mar 31, 2025 2024 FY Mar 31, 2024 2023 FY Mar 31, 2023 2022 FY Mar 31, 2022 2021 FY Mar 31, 2021 2020 FY Mar 31, 2020 2019 FY
Depreciation & Amortization
- - - - - -
EBITDA
-438.15 -282.71 -218.28 -156.03 -108.12 -66.08
Earnings Per Share (Basic)
-2.73 -1.88 -1.71 -1.43 - -
Diluted EPS
-2.73 -1.88 -1.71 -1.43 - -
Weighted Average Shares
151.57 138.10 123.08 109.68 - -
Diluted Weighted Avg Shares
151.57 138.10 123.08 109.68 - -
Comprehensive Income
-414.29 -258.28 -210.51 -156.03 -107.71 -66.75